Smooth muscle tissue contraction pathways

Smooth muscle tissue contraction pathways encompass the integrated signaling networks that regulate the mechanical tension of non-striated muscle cells found in the vascular, respiratory, gastrointestinal, and urogenital systems (StatPearls, 2023). The core mechanism is the calcium-calmodulin-mediated activation of myosin light chain kinase (MLCK), which phosphorylates the 20-kDa regulatory light chain of myosin, enabling interaction with actin (Nature Reviews Molecular Cell Biology, 2003). This process is further modulated by calcium sensitization pathways, notably the RhoA/Rho-kinase (ROCK) and Protein Kinase C (PKC) cascades, which inhibit myosin light chain phosphatase (MLCP), thereby maintaining contraction even at low calcium levels (Journal of Applied Physiology, 2001). In clinical practice, these pathways are major therapeutic targets for treating hypertension via calcium channel blockers, asthma via beta-2 adrenergic agonists, and overactive bladder via muscarinic antagonists (PubMed, 2018). Understanding the crosstalk between these diverse signaling inputs is critical for developing selective agents that can modulate tissue-specific tone without causing systemic adverse effects like profound hypotension or cardiac arrhythmias (Frontiers in Physiology, 2021).

Other names

Smooth muscle contractionExcitation-contraction coupling in smooth muscleMyogenic response signaling

Drugs targeting these pathways act by modulating intracellular calcium concentrations, inhibiting kinases such as myosin light chain kinase (MLCK) or Rho-kinase (ROCK), or activating phosphatases to alter the phosphorylation state of the myosin light chain, thereby inducing relaxation or contraction.